Acquisition and Divestitures - On July 25, 2024, the company acquired Scienture LLC, a specialty pharmaceutical company focused on cardiovascular and central nervous system diseases, which launched its first product for hypertension and is commercializing a second product for opioid overdose [406]. - The company completed the acquisition of Superlatus on July 31, 2023, with shareholders receiving an aggregate value of $225,000,169 at the time of closing [413]. - The company divested several subsidiaries, including Community Specialty Pharmacy and Alliance Pharma Solutions, to streamline operations and focus on high-growth opportunities in the branded and specialty pharma markets [422]. Financial Performance - As of December 31, 2025, the company had cash and cash equivalents of $6,662,008 and positive working capital of approximately $5,181,000, an improvement of approximately $6,782,000 from a working capital deficit of $(1,601,416) as of December 31, 2024 [427]. - Revenues for the year ended December 31, 2025, were $431,609, an increase of $294,966 or approximately 216% compared to $136,643 in 2024, driven by initial sales of ARBLI™ [435]. - Net cash used in operating activities from continuing operations for the year ended December 31, 2025 was $13,382,482, compared to $13,286,163 for the year ended December 31, 2024, with a net loss of $43,507,142 being the primary driver [430]. - The company reported a net cash provided by financing activities from continuing operations of $19,733,595 for the year ended December 31, 2025, compared to a net cash used of approximately $12,980,000 for 2024 [432]. - The company had an accumulated deficit of $80,551,237 as of December 31, 2025, indicating ongoing financial challenges despite improvements in working capital [427]. - For the year ended December 31, 2025, adjusted EBITDA was $(5,384,274), a significant decrease from $17,820,898 in 2024 [449]. - The net loss for 2025 was $(41,512,264), compared to a net income of $9,065,798 in 2024 [449]. Operating Expenses and Costs - Total operating expenses increased to $42,922,324 in 2025 from $14,707,020 in 2024, primarily due to non-cash impairment charges of $26,346,050 recognized in 2025 [436]. - Professional fees rose by $949,490 to $2,407,822 in 2025, mainly due to higher external consulting costs related to commercialization activities [436]. - Interest expense increased to $4,083,206 in 2025 from $1,335,631 in 2024, reflecting a full year of amortization of debt discount and interest on convertible notes [437]. - The company recognized non-cash impairment charges of $26,346,050 in 2025, impacting adjusted EBITDA [449]. - Depreciation and amortization expenses increased to $491,781 in 2025 from $53,361 in 2024 [449]. - Stock-based compensation (non-cash) increased to $6,378,981 in 2025 from $4,623,878 in 2024 [449]. Product Development and Sales - The company commenced sales of ARBLI™ in the third quarter of 2025 following FDA approval in March 2025, marking a significant milestone in its product offerings [435]. - The company expects to fund operations for at least the next twelve months from its existing cash balance and revenues generated from the commercialization of ARBLI™, which commenced in Q3 2025, and REZENOPY, anticipated to start in Q2 2026 [424]. - The company anticipates revenue growth from ARBLI™ and REZENOPY in 2026, contributing to its liquidity outlook [428]. Tax and Regulatory Matters - The company recognized an income tax benefit of $1,994,878 in 2025, reflecting changes in deferred tax liabilities attributable to the impairment charges [437]. - The company is classified as a "smaller reporting company" and is not required to provide certain market risk disclosures [452]. - The company did not have any off-balance sheet arrangements during the reported periods [450].
Scienture Holdings, Inc.(SCNX) - 2025 Q4 - Annual Report